277 related articles for article (PubMed ID: 26476173)
1. Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed.
Ando H; Kobayashi S; Abu Lila AS; Eldin NE; Kato C; Shimizu T; Ukawa M; Kawazoe K; Ishida T
J Control Release; 2015 Dec; 220(Pt A):29-36. PubMed ID: 26476173
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model.
Eldin NE; Abu Lila AS; Kawazoe K; Elnahas HM; Mahdy MA; Ishida T
Eur J Pharm Sci; 2016 Jan; 81():60-6. PubMed ID: 26415830
[TBL] [Abstract][Full Text] [Related]
3. Liposomal pemetrexed: formulation, characterization and in vitro cytotoxicity studies for effective management of malignant pleural mesothelioma.
Essam Eldin N; Elnahas HM; Mahdy MA; Ishida T
Biol Pharm Bull; 2015; 38(3):461-9. PubMed ID: 25757929
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.
Abu Lila AS; Kato C; Fukushima M; Huang CL; Wada H; Ishida T
Int J Oncol; 2016 Apr; 48(4):1399-407. PubMed ID: 26847426
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma.
Amano Y; Ohta S; Sakura KL; Ito T
Eur J Pharm Sci; 2019 Oct; 138():105008. PubMed ID: 31302213
[TBL] [Abstract][Full Text] [Related]
6. Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy.
Abu Lila AS; Fukushima M; Huang CL; Wada H; Ishida T
Mol Pharm; 2016 Nov; 13(11):3955-3963. PubMed ID: 27740765
[TBL] [Abstract][Full Text] [Related]
7. Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.
Sonvico F; Barbieri S; Colombo P; Barocelli E; Mucchino C; Cantoni AM; Petronini PG; Rusca M; Carbognani P; Ampollini L
Eur J Pharm Sci; 2018 Oct; 123():89-97. PubMed ID: 30030099
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
[TBL] [Abstract][Full Text] [Related]
10. Prolonged retention of liposomes in the pleural cavity of normal mice and high tumor distribution in mice with malignant pleural effusion, after intrapleural injection.
Marazioti A; Papadia K; Giannou A; Stathopoulos GT; Antimisiaris SG
Int J Nanomedicine; 2019; 14():3773-3784. PubMed ID: 31213801
[No Abstract] [Full Text] [Related]
11. Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.
Petrella F; Coccè V; Masia C; Milani M; Salè EO; Alessandri G; Parati E; Sisto F; Pentimalli F; Brini AT; Pessina A; Spaggiari L
Biomed Pharmacother; 2017 Mar; 87():755-758. PubMed ID: 28153512
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
14. Preparation and Evaluation of Stearylamine-Bearing Pemetrexed Disodium-Loaded Cationic Liposomes In Vitro and In Vivo.
He K; Liu J; Gao Y; Hao Y; Yang X; Huang G
AAPS PharmSciTech; 2020 Jul; 21(5):193. PubMed ID: 32661922
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.
Li Q; Wang W; Machino Y; Yamada T; Kita K; Oshima M; Sekido Y; Tsuchiya M; Suzuki Y; Nan-Ya K; Iida S; Nakamura K; Iwakiri S; Itoi K; Yano S
Cancer Sci; 2015 Jan; 106(1):102-7. PubMed ID: 25421609
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
Kuryk L; Haavisto E; Garofalo M; Capasso C; Hirvinen M; Pesonen S; Ranki T; Vassilev L; Cerullo V
Int J Cancer; 2016 Oct; 139(8):1883-93. PubMed ID: 27287512
[TBL] [Abstract][Full Text] [Related]
18. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
[TBL] [Abstract][Full Text] [Related]
19. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
Maehara S; Usuda J; Ishizumi T; Ichinose S; Ohtani K; Inoue T; Imai K; Furumoto H; Kudo Y; Kajiwara N; Ohira T; Ikeda N
Int J Oncol; 2015 Feb; 46(2):741-9. PubMed ID: 25385189
[TBL] [Abstract][Full Text] [Related]
20. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
